Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples

Oncotarget

Volumn 7, Issue 33, 2016, Pages 53102-53115

  Martinez Garcia, Elena ^a   Lesur, Antoine ^b   Devis, Laura ^a   Campos, Alexandre Rosa ^c   Cabrera, Silvia ^d   van Oostrum, Jan ^b   Matias Guiu, Xavier ^e   Gil Moreno, Antonio ^a,d   Reventos, Jaume ^a,f   Colas, Eva ^a,e   Domon, Bruno ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c BURNHAM INSTITUTE   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Biomarker verification; Endometrial cancer; High resolution accurate mass spectrometry; Parallel reaction monitoring; Uterine aspirate

Indexed keywords

TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; ASPIRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; PARALLEL REACTION MONITORING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ENDOMETRIUM; ENDOMETRIUM TUMOR; METABOLISM; METHODOLOGY; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; PROTEOMICS; REPRODUCIBILITY; UTERUS;

BASE SEQUENCE; BIOMARKERS, TUMOR; BIOPSY, NEEDLE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MASS SPECTROMETRY; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; UTERUS;

EID: 84982245280     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10632     Document Type: Article

References (42)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7-30.
2. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, Group EGW. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2013; 24:vi33-38.
3. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. The Lancet. 2005; 366:491-505.
4. Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG. 2002; 109:313-321.
5. Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol. 2002; 14:409-415.
6. DeSouza LV, Grigull J, Ghanny S, Dube V, Romaschin AD, Colgan TJ, Siu KW. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Molecular & cellular proteomics: MCP. 2007; 6:1170-1182.
7. Li Z, Zhao X, Bai S, Wang Z, Chen L, Wei Y, Huang C. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Molecular & cellular proteomics: Mol Cell Proteomics. 2008; 7:1810-1823.
8. Monge M, Colas E, Doll A, Gil-Moreno A, Castellvi J, Diaz B, Gonzalez M, Lopez-Lopez R, Xercavins J, Carreras R, Alameda F, Canals F, Gabrielli F, et al. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis. 2009; 30:1288-1297.
9. Casado-Vela J, Rodriguez-Suarez E, Iloro I, Ametzazurra A, Alkorta N, Garcia-Velasco JA, Matorras R, Prieto B, Gonzalez S, Nagore D, Simon L, Elortza F. Comprehensive proteomic analysis of human endometrial fluid aspirate. J Proteome Res. 2009; 8:4622-4632.
10. Ametzazurra A, Matorras R, Garcia-Velasco JA, Prieto B, Simon L, Martinez A, Nagore D. Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis. Human reproduction. 2009; 24:954-965.
11. Salamonsen LA, Edgell T, Rombauts LJ, Stephens AN, Robertson DM, Rainczuk A, Nie G, Hannan NJ. Proteomics of the human endometrium and uterine fluid: a pathway to biomarker discovery. Fertility and sterility. 2013; 99: 1086-1092.
12. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24:971-983.
13. Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, Bateman NW, Allard J, Miller C, Sun M, Flint MS, Zahn C, Oliver J, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011; 121:586-594.
14. Voisin SN, Krakovska O, Matta A, DeSouza LV, Romaschin AD, Colgan TJ, Siu KW. Identification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQ. PloS one. 2011; 6:e16352.
15. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. British journal of cancer. 2011; 104: 1418-1425.
16. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer. 2010; 116:843-851.
17. Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini PG, D'Ambrogio G, Genazzani AR. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. Journal of experimental & clinical cancer research: CR. 2001; 20:239-246.
18. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer. 2000; 88:2774-2781.
19. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, et al. A targeted proteomicsbased pipeline for verification of biomarkers in plasma. Nat Biotechnol. 2011; 29:625-634.
20. Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation-quality assurance and control of protein biomarker assays. Mol Oncol. 2014; 8:840-858.
21. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clinical applications. 2008; 2:1386-1402.
22. Schwartz EB, Granger DA. Transferrin enzyme immunoassay for quantitative monitoring of blood contamination in saliva. Clinical chemistry. 2004; 50:654-656.
23. Aasebo E, Opsahl JA, Bjorlykke Y, Myhr KM, Kroksveen AC, Berven FS. Effects of blood contamination and the rostrocaudal gradient on the human cerebrospinal fluid proteome. PloS one. 2014; 9:e90429.
24. Gallien S, Domon B. Detection and quantification of proteins in clinical samples using high resolution mass spectrometry. Methods. 2015; 81:15-23.
25. Hacker NF, Gambone JC, Hobel CJ. Hacker & Moore's Essentials of Obstetrics and Gynecology. Elsevier Health Sciences. 2009:1867.
26. Dorum A, Kristensen GB, Langebrekke A, Sornes T, Skaar O. Evaluation of endometrial thickness measured by endovaginal ultrasound in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 1993; 72:116-119.
27. Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama A, Takano T, Niikura H, Ito K, Kadomatsu K, Hayashi S, Yaegashi N. Midkine and its clinical significance in endometrial carcinoma. Cancer Sci. 2008; 99:1125-1130.
28. Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G, Ma X, Sun D, Rohan T, Xue F. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol Oncol. 2013; 129:505-512.
29. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol. 2007; 107:58-65.
30. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Molecular & cellular proteomics: Mol Cell Proteomics. 2002; 1:845-867.
31. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. Journal of mass spectrometry: J Mass Spectrom. 2011; 46:298-312.
32. DeSouza LV, Romaschin AD, Colgan TJ, Siu KW. Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. Analytical chemistry. 2009; 81:3462-3470.
33. DeSouza LV, Taylor AM, Li W, Minkoff MS, Romaschin AD, Colgan TJ, Siu KW. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J Proteome Res. 2008; 7:3525-3534.
34. Gallien S, Kim SY, Domon B. Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM). Molecular & cellular proteomics: Mol Cell Proteomics. 2015; 14:1630-1644.
35. Kim YJ, Gallien S, El-Khoury V, Goswami P, Sertamo K, Schlesser M, Berchem G, Domon B. Quantification of SAA1 and SAA2 in lung cancer plasma using the isotypespecific PRM assays. Proteomics. 2015; 15:3116-3125.
36. Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda KA, Scott RJ, Falkenby LG, Cairns MJ, Larsen MR, Bradshaw RA, Hondermarck H. Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis. Molecular & cellular proteomics: Mol Cell Proteomics. 2015; 14:2316-2330.
37. Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E, 3rd, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nature genetics. 2013; 45:1386-1391.
38. Kim HJ, Lin D, Lee HJ, Li M, Liebler DC. Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays. Molecular & cellular proteomics: Mol Cell Proteomics. 2016; 15:682-691.
39. Lesur A, Domon B. Advances in high-resolution accurate mass spectrometry application to targeted proteomics. Proteomics. 2015; 15:880-890.
40. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: statistical guidelines for nested casecontrol studies. BMC medical research methodology. 2002; 2:4.
41. Wan KX, Vidavsky I, Gross ML. Comparing similar spectra: from similarity index to spectral contrast angle. Journal of the American Society for Mass Spectrometry. 2002; 13:85-88.
42. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behavioural brain research. 2001; 125:279-284.